Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Invasive Bladder Cancer × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 34 Carcinoma, Non-Small-Cell Lung 22 Melanoma 18 Squamous Cell Carcinoma of Head and Neck 16 Colorectal Neoplasms 15 Urinary Bladder Neoplasms 11 Lung Neoplasms 10 Liver Neoplasms 10 Breast Neoplasms 10 Biliary Tract Neoplasms 10 Small Cell Lung Carcinoma 9 Prostatic Neoplasms 9 Diabetes Mellitus, Insulin-Dependent, 12 9 Carcinoma, Renal Cell 9 Neoplasms 7 Cholangiocarcinoma 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Neoplasm Metastasis 5 Mesothelioma, Malignant 5 Fallopian Tube Neoplasms 5 Adenocarcinoma Of Esophagus 5 Uterine Cervical Neoplasms 4 Stomach Neoplasms 4 Recurrence 3 Mesothelioma 3 Kidney Neoplasms 3 Esophageal Squamous Cell Carcinoma 3 Endometrial Neoplasms 3

Interventions

tremelimumab 1 durvalumab 1 Sodium Chloride 1 Radiotherapy 1 Lidocaine 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03702179 2024-12-05

IMMUNOPRESERVE

Spanish Oncology Genito-Urinary Group

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡